Congress wants Vytorin ad info

Share this article:

Reps. John Dingell and Bart Stupak aren't only interested in Lipitor advertising. In the wake of the release of Enhance trial data, the duo sent letters to Merck and Schering-Plough vowing an investigation and making clear that DTC ads for the drug would be a major focus.

“Given the frequency of Vytorin advertisements, it concerns us that a study showing that Vytorin provides no increased benefit was not issued for nearly two years while (DTC ads) were carried on the airwaves,” they wrote. “This situation raises concerns that the drug companies and their advertisement agencies profited at the significant expense of patients' health.” 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.